Global Hepatitis B Therapeutics Market 2018-2022| Strategic Collaboration Between the Pharmaceutical Companies to Boost Growth| Technavio

LONDON--(BUSINESS WIRE)-- The global hepatitis B therapeutics market is expected to post a CAGR of over 2% during the period 2019-2023, according to the latest market research report by Technavio.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005654/en/

Technavio has released a new market research report on the global hepatitis B therapeutics market for the period 2018-2022. (Graphic: Business Wire)

A key factor driving the growth of the global hepatitis B therapeutics market is the increasing prevalence of hepatitis B in infants. According to the CDC. approximately 90% of infected infants become chronically infected. compared with 2%-6% of adults. Infants who get hepatitis B become chronically infected, and about 1 out of 4 of them die within a short period. Therefore, the companies are developing several drugs and vaccines against hepatitis B virus, which, in turn, is fueling the growth of the global hepatitis B therapeutics market.

This market research report on the global hepatitis B therapeutics 2019-2023 also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

In this report, Technavio highlights the strategic collaboration between the pharmaceutical companies as one of the key emerging trends in the global hepatitis B therapeutics market:

Global hepatitis B therapeutics market: Strategic collaboration between the pharmaceutical companies

Global hepatitis B therapeutics market is fragmented, as several pharmaceutical companies are developing drugs for the treatment of hepatitis B. In addition, many companies are forming strategic collaborations to increase their research toward the hepatitis B drug development. For instance, in October 2018, Arrowhead pharmaceuticals entered into a license and collaboration agreement with Janssen Pharmaceuticals to develop and commercialize ARO-HBV. Therefore, the strategic collaborations between companies will lead to an increase in the growth of the global hepatitis B therapeutics market during the forecast period.

“With the increase in the prevalence of hepatitis B, the demand for treatment of the disease is becoming prominent. Therefore, some of the government and non-government organizations are taking the initiative to bring awareness about hepatitis B, which, in turn, is proving to beneficial for the global hepatitis B therapeutics market,” says a senior analyst at Technavio for research on infectious and rare diseases.

Global hepatitis B therapeutics market: Segmentation analysis

This market research report segments the global hepatitis B therapeutics market by application (drugs, and vaccines) and geographical regions (APAC, EMEA, and the Americas).

The Americas led the market in 2018 with a market share of over 62%, followed by EMEA and APAC respectively. Although the APAC held the smallest share of the market in 2018, it is expected to register the highest incremental growth during the forecast period.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

• Market ecosystem
• Market characteristics
• Market segmentation analysis

Market Sizing

• Market definition
• Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

• Regional comparison
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005654/en/